Back

Disease progression and outcomes in patients with transthyretin amyloid cardiomyopathy receiving tafamidis

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Expanding insights from heart failure registries and surveys Epidemiology, Prognosis, Outcome HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speakers

Photo
Professor Marianna Fontana

University College London, London (United Kingdom of Great Britain & Northern Ireland)

Photo
Doctor Valentina Marino

(Italy)

5 More presentations in this session

Presentation thumbnail
Age-related disparities in heart failure: insights into clinical profiles, treatment gaps, and outcomes from a multi-center and multi-ethnic study
Doctor A. Koh (Kuching, MY)
Abstract Slides Video
Presentation thumbnail
Non-conventional parameters from holter ECG: a promising tool for heart failure risk stratification
Doctor S. Duca (Iasi, RO)
Abstract Slides Video
Presentation thumbnail
The epidemiology of heart failure in Hungary: basic data and temporal trends from the Hungarian nationwide epidemiological study (HF-EPI-HUN) over a 15-year period (2009-2023)
Doctor R. Sepp (Szeged, HU)
Abstract Slides Video
Presentation thumbnail
Evaluating survival outcomes across NT-proBNP levels and introduction of a high alert pathway: an island wide experience
Doctor A. Henry (St Helier, JE)
Abstract Slides Video
Presentation thumbnail
Clinical characteristics, management trends, and outcomes of acute heart failure in Korea: Insights from the SMILE-HF Registry
Associate Professor S. Lee (Seoul, KR)
Abstract Slides Video

Access the full session

Session thumbnail
Expanding insights from heart failure registries and surveys

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Tafamidis treatment for transthyretin amyloid cardiomyopathy: results from an open-label, early-access, long-term study extension in an all-comers population
thumbnail
Congress Presentation
Evolution over time of cardiac biomarkers, electrocardiographic and echocardiographic features in a large cohort of patients with wild-type transthyretin cardiac amyloidosis treated with tafamidis
thumbnail
Congress Presentation
12-Month effect of Tafamidis on the clinical progression of cardiac amyloidosis in a single centre cohort

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources